Cargando…
Neoadjuvant immunotherapy for muscle invasive urothelial bladder carcinoma: will it change current standards?
Immunotherapy, in the form of immune checkpoint inhibitors (ICI), has shown activity in metastatic urothelial bladder carcinoma, resulting in the approval of several ICI agents in the first- and second-line settings. This has led to an increased interest in studying their efficacy in the neoadjuvant...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273398/ https://www.ncbi.nlm.nih.gov/pubmed/34290827 http://dx.doi.org/10.1177/17562872211029779 |